Search from website

Antibody development

Leave your inquiry here:

Contact Luka

Name(Required)

Antibody discovery and engineering

From antibody humanization and reformatting to afucosylated bispecific antibodies – we have developed and produced them all. Our technology and experience gives us an ability to discover antibodies against difficult multi-pass transmembrane proteins. 

Icosagen provides antibody discovery and development services, using proprietary technologies. 

Let's discuss antibody discovery!

Antibody discovery is powered by HybriFree technology

Our proprietary HybriFree technology is based on B-cell cloning, and is used for efficient discovery of monoclonal antibodies and their immediate production in mammalian cells. 

HybriFree makes antibody discovery rapid and flexible, and allows cloning antibodies even from recovered patients’ PBMCs and existing hybridomas.

Why choose HybriFree for antibody discovery?

SEAMLESS
TRANSITION

SEAMLESS TRANSITION

From discovery to large scale production.

FAST in vivo
APPROACH

FAST in vivo APPROACH

After immunization stage, biologically active antibodies with optimal physicochemical properties can be delivered as fast as 8 to 9 weeks.

IMMUNIZATION
AGILITY

IMMUNIZATION AGILITY

Immunization of chickens with DNA, peptides, proteins or VLPs can be used to develop antibodies against hard-to-express proteins.

FLEXIBLE

FLEXIBLE

All identified sequences can be used for production of different immune molecules (bi-specifics, chimeras, antibody fragmens etc.)

COMPLEX
TARGETS

WORKS WITH COMPLEX TARGETS

Integral membrane proteins as feasible targets.

HybriFree workflow

REMEMBER: ANTIGEN MATTERS! Even the smallest difference between an antigen and the natural target protein will affect the antibody specificity and biological function.

Our HybriFree technology delivers high quality antibodies suitable from IVD purposes, in pre-clinical and clinical in vitro and in vivo studies, to even for developing human biopharmaceutical drugs

Hybridoma sequencing platform — HybriRescue

We clone antibodies from hybridomas, provided by our customers, and produce them at requested scales.

In addition, we deliver the cDNA sequence encoding the antibody variable heavy (VH) and light (VL) domains.

ANTIBODY
ENGINEERING

ANTIBODY ENGINEERING

Essential for monoclonal antibody engineering, humanization, function optimization or patent applications.

DELIVERS
SEQUENCE

DELIVERS ANTIBODY SEQUENCE

With determined antibody sequence there is always opportunity to reproduce it, which eliminates the risk of excellent antibodies being permanently lost due to loss of cell culture.

PATENT
APPLICATION

PATENT APPLICATION

Patent the sequences of your unique variable domains that provides opportunities for investing in R&D.

HybriRescue workflow

Humanization of antibodies discovered from non-humanized animals or libraries is a necessity for their use as therapeutics. The challenge is to retain the desired specificity and affinity, while engineering away their immunogenic properties.

Antibody humanization

Our humanization platform service benefits from a proprietary software developed in collaboration with the University of Tartu.

We routinely humanize variable regions and framework sequences from any species, using any reference sequence as the basis. Key residues important for the VH/VL interface and antibody structure are maintained as much as possible in the humanized variants. Humanized sequences are screened to be free of motifs that are prone to glycosylation, deamidation or other PTMS.

FLEXIBILITY

FLEXIBILITY

Antibody variable regions from the light (VL) and heavy (VH) chains can be humanized from any species.

VALIDATED
SYSTEM

VALIDATED

In-house humanization and production cycle studies have provided antibodies with great titers and affinity database. We humanize all unconsolidated and non-human immunoglobulin variable region sequences.

FREE OF MOTIFS

FREE OF MOTIFS

Humanized sequences are screened to be free of motifs that can be prone to glycosylation or deamination.

KEY RESIDUES
MAINTAINED

KEY RESIDUES MAINTAINED

Key residues important for the VH/VL interface and structure are maintained as much as possible in the humanized variants.

DEVELOPABILITY

DEVELOPABILITY

Humanized antibodies show ideal developability profile compared to parental antibody.

Humanization workflow

Keep only the best binders with highest production yields

Antibody
development
Protein
production
Cell line
development
Analytics

Ask for your custom solution

Shopping Cart